Compare iShares MSCI Australia ETF (EWA) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Gilead Sciences, Inc. — how do they compare? iShares MSCI Australia ETF trades at $28.59 (market cap $1.17B), while Gilead Sciences, Inc. trades at $151.28 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 155.9× iShares MSCI Australia ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while iShares MSCI Australia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and Gilead Sciences, Inc. for 111 Days on average.
| EWA | GILD | |
|---|---|---|
Market Cap | $1.17B | $182.40B |
Volume | 2,121,231 | 4,469,821 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $155.80 |
52-Week Low | $24.95 | $116.74 |
Typical Hold Time | 61 Days | 111 Days |
Enterprise Value | — | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.56, up 1.17% today, but technical indicators are bearish with all moving averages signaling sell. The ETF provides exposure to Australian equities, heavily weighted toward commodities and financials. Recent news highlights institutional selling by Squarepoint Ops LLC and broader Australian market pressures from inflation concerns due to rising oil prices.
The outlook remains cautious amid bearish technicals and macroeconomic headwinds, though some analysts see upside potential from commodity strength. Risks include persistent inflation, tight monetary policy, and reliance on raw material exports. Investors should weigh technical weakness against long-term commodity-driven growth prospects.
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
